European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.
Conversion of Biomarkers Between Primary Breast Cancer Tumor and Relapse May Have Prognostic Value
ESMO 2016
In a retrospective study of 45 breast cancer patients, the differential expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 is evaluated in primary and relapsed tumors. The conversion rate of these biomarkers and their prognostic relevance are assessed. Read More ›
Improved Sensitivity to Endocrine Therapy Following Treatment with Eribulin Mesylate
ESMO 2016
Eribulin mesylate is an inhibitor of microtubule dynamics that may play a role in reducing the abnormality of the tumor microenvironment (ie, increasing oxygenation). As hypoxic conditions may contribute to drug resistance, it is hypothesized that eribulin may enhance the efficacy of other therapies. In this study, the effects of eribulin on 2 endocrine therapies were evaluated. Read More ›
Exploring the Relationship Between Progression-Free Survival and Overall Survival in Breast Cancer Patients Treated with Fulvestrant or Anastrozole
ESMO 2016
Progression-free survival (PFS) is often used as a surrogate for overall survival (OS) due to the challenges of measuring OS in relatively short-term trials, and is a practice that has been supported by previous analyses of breast cancer data. This analysis further examines the relationship between PFS and OS in advanced breast cancer. Read More ›

Page 11 of 13


© Amplity, Inc. All Rights Reserved. Privacy Policy